BRPI0915247A2 - método para reduzir o complexo de oxldl-beta-2-glicoproteína circulante e mieloperoxidase circulante no soro humano, e, processo para a fabricação de uma composição de óleo dietética" - Google Patents

método para reduzir o complexo de oxldl-beta-2-glicoproteína circulante e mieloperoxidase circulante no soro humano, e, processo para a fabricação de uma composição de óleo dietética"

Info

Publication number
BRPI0915247A2
BRPI0915247A2 BRPI0915247A BRPI0915247A BRPI0915247A2 BR PI0915247 A2 BRPI0915247 A2 BR PI0915247A2 BR PI0915247 A BRPI0915247 A BR PI0915247A BR PI0915247 A BRPI0915247 A BR PI0915247A BR PI0915247 A2 BRPI0915247 A2 BR PI0915247A2
Authority
BR
Brazil
Prior art keywords
circulating
myeloperoxidase
beta
manufacturing
oil composition
Prior art date
Application number
BRPI0915247A
Other languages
English (en)
Inventor
Bomi P Framroze
Original Assignee
Bomi P Framroze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bomi P Framroze filed Critical Bomi P Framroze
Publication of BRPI0915247A2 publication Critical patent/BRPI0915247A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0915247A 2008-11-14 2009-11-10 método para reduzir o complexo de oxldl-beta-2-glicoproteína circulante e mieloperoxidase circulante no soro humano, e, processo para a fabricação de uma composição de óleo dietética" BRPI0915247A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11482308P 2008-11-14 2008-11-14
PCT/IB2009/007669 WO2010055419A2 (en) 2008-11-14 2009-11-10 A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis

Publications (1)

Publication Number Publication Date
BRPI0915247A2 true BRPI0915247A2 (pt) 2016-02-16

Family

ID=42170470

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915247A BRPI0915247A2 (pt) 2008-11-14 2009-11-10 método para reduzir o complexo de oxldl-beta-2-glicoproteína circulante e mieloperoxidase circulante no soro humano, e, processo para a fabricação de uma composição de óleo dietética"

Country Status (11)

Country Link
US (1) US9446013B2 (pt)
EP (1) EP2355812B1 (pt)
JP (2) JP2012508791A (pt)
KR (1) KR20110098909A (pt)
CN (1) CN102202661A (pt)
AU (1) AU2009315314B2 (pt)
BR (1) BRPI0915247A2 (pt)
CA (1) CA2743434C (pt)
DK (1) DK2355812T3 (pt)
MX (1) MX2011005077A (pt)
WO (1) WO2010055419A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
NO344004B1 (en) * 2017-06-23 2019-08-12 Olivita As Combination of oils
US20220403442A1 (en) * 2019-10-21 2022-12-22 President And Fellows Of Harvard College Compositions and methods for detection of oxidizable analytes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
GB2238476A (en) * 1989-11-04 1991-06-05 K T Lalvani Therapeutic aquatic animal and garlic products
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
DE19855426A1 (de) * 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
JP2001346517A (ja) * 2000-06-02 2001-12-18 K-Tac Planners Co Ltd 食用油脂。
DE20105126U1 (de) * 2001-03-23 2002-01-31 Bartz, Volker, 35440 Linden Fischöl zur oralen Einnahme
GB0210212D0 (en) 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
CA2485116C (en) * 2002-05-03 2013-02-05 Pronova Biocare As Use of epa and dha in secondary prevention
ES2254018B2 (es) * 2004-11-16 2009-01-01 Universidad Autonoma De Madrid Mezcla oleosa de ingredientes bioactivos naturales para la preparacion de un producto alimenticio enriquecido.
ES2333254T3 (es) * 2005-04-29 2010-02-18 Vinorica S.L. Suplemento alimenticio o alimento funcional que comprende combinacion de aceites.
EP1964554A1 (en) * 2005-11-30 2008-09-03 Katry Inversiones, S.L. Lipid mixture and use thereof for the preparation of a product that is intended for enteral or oral administration
EP1800675B1 (en) * 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
JP5099808B2 (ja) * 2006-05-29 2012-12-19 独立行政法人農業・食品産業技術総合研究機構 脂質代謝改善用組成物
WO2008088415A1 (en) * 2006-10-18 2008-07-24 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids for reduction of lp-pla2 levels
US20090270502A1 (en) * 2007-01-11 2009-10-29 Carotino Sdn. Bhd. Method for Lowering Risk of Cardiovascular Diseases

Also Published As

Publication number Publication date
JP2012508791A (ja) 2012-04-12
AU2009315314B2 (en) 2013-04-18
AU2009315314A1 (en) 2010-05-20
CN102202661A (zh) 2011-09-28
CA2743434C (en) 2015-04-21
MX2011005077A (es) 2011-05-25
EP2355812A2 (en) 2011-08-17
WO2010055419A3 (en) 2010-09-10
EP2355812B1 (en) 2019-07-10
EP2355812A4 (en) 2012-04-18
US9446013B2 (en) 2016-09-20
WO2010055419A2 (en) 2010-05-20
US20110207821A1 (en) 2011-08-25
CA2743434A1 (en) 2010-05-20
KR20110098909A (ko) 2011-09-02
DK2355812T3 (da) 2019-10-07
JP2015091855A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0915247A2 (pt) método para reduzir o complexo de oxldl-beta-2-glicoproteína circulante e mieloperoxidase circulante no soro humano, e, processo para a fabricação de uma composição de óleo dietética"
BRPI0919192A2 (pt) Uso de lipídio, composição nutricional, e, processo para a produção de uma composição nutricional
BRPI0819375A2 (pt) "método para controlar a concentração de butanol, processo, método para a reciclagem de pelo menos um caldo de fermentação e composição intermediária"
BRPI0916015A2 (pt) "palmilha, método para fabricação de uma palmilha e calçado"
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI0808024A2 (pt) Método para desengomar uma composição de óleo, e, processo para desengomadura de óleo
BRPI0816640A2 (pt) "método para produzir produtos de proteína estável ácida e produtos assim produzidos"
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0814503A2 (pt) composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0915986A2 (pt) composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo
BRPI0811750A2 (pt) Método para produzir um inversor de enriquecimento-empobrecimento, e, inversor
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0809690A2 (pt) Composição de lubrificante, e, método
BRPI0822955A2 (pt) método para operar um elevdor em um modo de emergência, e, elevador.
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0911681A2 (pt) composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula
BR112012002608A2 (pt) composição lubrificante, e, método para melhorar o desempenho de uma composição lubrificante.
BRPI0817727A2 (pt) composição de graxa lubrificante, e, método para preparar uma composição de graxa
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0714474A2 (pt) "aditivo alimentar, gênero alimenticio fortificado com fibras, método para fortificar um gênero alimenticio com fibras e bebida forticada com fibra"
BRPI0717753A2 (pt) Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
BRPI0914465A2 (pt) "método para buscar conteúdos multimídia na internet"
BRPI0918680A2 (pt) "composição de proteína de soja hidrolisada, fração da proteína, produto alimentício, processo para a fabricação de uma fração de proteína, processo para a produção de um produto de proteína e produto alimentício"
BRPI0819642A2 (pt) Método para a formação de uma dentadura para um paciente em uma única visita, e, dentadura

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL